IMS 2023 | Idecabtagene vicleucel for R/R multiple myeloma with renal impairment
Surbhi Sidana, MD, Stanford University, Stanford, CA, shares some insights into a retrospective study evaluating the safety and efficacy of idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory (R/R) multiple myeloma and renal impairment. This study found that the safety and efficacy of ide-cel in patients with renal impairment is almost comparable to that of patients without renal impairment, with no differences observed in response rates or progression-free survival (PFS). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
